Abstract

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Reasons for Discordance Among Imaging‐based Response Criteria In Lymphoma Patients Receiving CAR T‐cell Therapy
J Ricke ... M Winkelmann
Hematological Oncology | VOL. 41
J Ricke, et. al.J Ricke ... M Winkelmann
01 Jun 2023
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
Veit Bücklein ... Michael Von Bergwelt-Baildon
Journal for ImmunoTherapy of Cancer | VOL. 11
Veit Bücklein, et. al.Veit Bücklein ... Michael Von Bergwelt-Baildon
01 Oct 2023
Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
Tim Struessmann ... Florian Scherer
Blood | VOL. 142
Tim Struessmann, et. al.Tim Struessmann ... Florian Scherer
28 Nov 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
Christian Schmidt ... Marion Subklewe
Cancer Imaging | VOL. 23
Christian Schmidt, et. al.Christian Schmidt ... Marion Subklewe
15 May 2023
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome-like acute lymphoblastic leukemia.
Zicong Huang ... Hongsheng Zhou
HemaSphere | VOL. 8
Zicong Huang, et. al.Zicong Huang ... Hongsheng Zhou
01 May 2024
Interplay between α-thalassemia and β-hemoglobinopathies: Translating genotype-phenotype relationships into therapies.
Jim Vadolas ... George Grigoriadis
HemaSphere | VOL. 8
Jim Vadolas, et. al.Jim Vadolas ... George Grigoriadis
01 May 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Fabio Efficace ... Amer M Zeidan
HemaSphere | VOL. 8
Fabio Efficace, et. al.Fabio Efficace ... Amer M Zeidan
01 May 2024
-
-
HemaSphere | VOL. 8
--
01 May 2024
View more papers